Document is current
Any future updates will be listed below
-
Authors
Neparidze, Natalia https://orcid.org/0000-0001-9038-077X
Wang, Rong
Zeidan, Amer M.
Podoltsev, Nikolai A. https://orcid.org/0000-0002-3657-778X
Shallis, Rory M. https://orcid.org/0000-0002-8542-2944
Ma, Xiaomei https://orcid.org/0000-0001-9472-8032
Davidoff, Amy J. https://orcid.org/0000-0001-8141-9249
Huntington, Scott F.
- License Information
-
More Information
Article History
Received: 4 April 2022
Revised: 14 May 2022
Accepted: 14 June 2022
First Online: 27 June 2022
Competing interests
: NN receives research funding from Janssen and Glaxo-Smith-Kline and has received honoraria from Eidos Therapeutics. NAP consulted for and received honoraria from Alexion, Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol-Myers Squibb, CTI BioPharma, PharmaEssentia, Constellation pharmaceuticals, Cogent biosciences, AbbVie. NAP received research funding (all to the institution) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, Kartos Therapeutics. RMS consulted for and received honoraria from Bristol-Myers Squibb. XM received research funding (institutional) from Celgene/Bristol-Myers Squibb and consults for Bristol-Myers Squibb.
Free to read: This content has been made available to all.
